According to DPI developer Iconovo, TOA Pharmaceutical has signed a new agreement for the use of an Iconovo dry powder inhaler for a feasibility study. TOA will pay €202,000 over the next year for use of the device in a development project for a generic aimed at the Japanese market. Iconovo did not specify which of its devices will be used in this new feasibility … [Read more...] about TOA Pharmaceutical extends its agreement with Iconovo
News
Brigham and Women’s Hospital announces Phase 1 trial of intranasal vaccine for Alzheimer’s
Brigham and Women’s Hospital (BWH) has announced an upcoming clinical trial of an intranasal vaccine for the prevention and treatment of Alzheimer’s disease (AD). The SAD trial is expected to enroll 16 early-staged Alzheimer's patients aged 60-85 who will each get two doses of the vaccine, with the second dose administered one week following the first dose. The … [Read more...] about Brigham and Women’s Hospital announces Phase 1 trial of intranasal vaccine for Alzheimer’s
Akari Therapeutics chooses Inhalation Sciences for PK study of inhaled Nomacopan
According to Inhalation Sciences (ISAB), Akari Therapeutics has chosen ISAB's CRO, Inhalation Research Services, to conduct a pharmacokinetic study of Akari's Nomacopan, a C5 and LTB4 inhibitor that the company is evaluating as an inhaled therapy for the treatment of exacerbations in COPD and asthma. The PK study will be conducted using an isolated perfused lung (IPL) … [Read more...] about Akari Therapeutics chooses Inhalation Sciences for PK study of inhaled Nomacopan
Padagis launches generic version of Zomig nasal spray
Padagis (formerly Perrigo's generic prescription pharmaceutical business) has announced the launch of its generic version of Zomig zolmitriptan nasal spray for the treatment of migraine headaches in patients aged 12 and older. Altaris acquired Padagis from Perrigo in July 2021, and the FDA approved Padagis' ANDA for the unit dose nasal spray on September 30, 2021. … [Read more...] about Padagis launches generic version of Zomig nasal spray
Hovione to increase global capacity by 25%
CDMO Hovione said that it is investing $170 million to increase overall capacity at its manufacturing facilities in Portugal, Ireland, and the US by about 25% to meet strong demand. According to the company, its facilities expansion coincides with the addition of about 300 positions to its workforce. Hovione, which offers a full range of development and manufacturing … [Read more...] about Hovione to increase global capacity by 25%
DDL 2021 to offer a mix of live and on-demand content
For the second year, the Drug Delivery to the Lungs conference will take place virtually as a result of the COVID-19 pandemic. The conference will include both live and recorded scientific presentations, live discussion sessions, and a digital exhibition happening online December 8-10. The meeting will open at 10:00 a.m. UK time on each of the three days, and the live … [Read more...] about DDL 2021 to offer a mix of live and on-demand content
Phase 1 trial of Pneumagen’s Neumifil nasal spray gets underway
Pneumagen has announced the initiation of a Phase 1 SAD/MAD study of its Neumifil carbohydrate binding module (mCBM) nasal spray, which the company is developing for the prevention and treatment of viral respiratory infections. The company said that it expects topline results to be available in the first half of 2022. At the beginning of 2021, Pneumagen announced … [Read more...] about Phase 1 trial of Pneumagen’s Neumifil nasal spray gets underway
Birmingham Biotech licenses antiviral nasal spray from the University of Birmingham
Birmingham Biotech said that it has licensed a carrageenan/gellan antiviral nasal spray from the University of Birmingham and intends to market the spray in the UK and in Asian countries for protection against COVID-19 starting in early 2022. The license excludes marketing rights in India but includes the rest of the world. Birmingham Biotech currently sells … [Read more...] about Birmingham Biotech licenses antiviral nasal spray from the University of Birmingham
Pulmatrix and Cipla resolve dispute over Pulmazole funding
According to Pulmatrix, a dispute between Pulmatrix and Cipla over funding related to the development of Pulmazole intraconazole DPI (PUR 1900) has been resolved. In May 2021, Pulmatrix announced that Cipla had failed to provide 50% of the development costs for Pulmazole and had therefore breached the terms of their development and commercialization agreement for the … [Read more...] about Pulmatrix and Cipla resolve dispute over Pulmazole funding
FDA tentatively approves Liquidia’s NDA for Yutrepia treprostinil DPI
According to Liquidia, the FDA has tentatively approved the company's NDA for its Yutrepia (LIQ861) treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH). The FDA had previously issued a complete response letter to the NDA in November 2020. Liquidia refiled the LIQ861 NDA in May 2021, and in August 2021, the agency completed a pre-approval … [Read more...] about FDA tentatively approves Liquidia’s NDA for Yutrepia treprostinil DPI